Changzhou Qianhong Biopharma CO.,LTD (002550.SZ)
CNY 5.95
(4.94%)
CNY 5.95
(4.94%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.79 Billion CNY | -22.13% |
| 2022 | 2.3 Billion CNY | 22.86% |
| 2021 | 1.87 Billion CNY | 12.43% |
| 2020 | 1.66 Billion CNY | -0.45% |
| 2019 | 1.67 Billion CNY | 26.74% |
| 2018 | 1.32 Billion CNY | 24.05% |
| 2017 | 1.06 Billion CNY | 37.23% |
| 2016 | 776.38 Million CNY | 2.55% |
| 2015 | 757.05 Million CNY | -7.07% |
| 2014 | 814.6 Million CNY | -5.36% |
| 2013 | 860.78 Million CNY | 18.14% |
| 2012 | 728.59 Million CNY | -1.23% |
| 2011 | 737.65 Million CNY | -35.56% |
| 2010 | 1.14 Billion CNY | 53.91% |
| 2009 | 743.79 Million CNY | 57.7% |
| 2008 | 471.64 Million CNY | 65.14% |
| 2007 | 285.59 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 461.1 Million CNY | 34.43% |
| 2024 Q3 | 352 Million CNY | -9.23% |
| 2024 Q2 | 387.81 Million CNY | -15.89% |
| 2023 FY | 1.79 Billion CNY | -22.13% |
| 2023 Q2 | 448.53 Million CNY | -26.25% |
| 2023 Q1 | 608.21 Million CNY | -7.1% |
| 2023 Q4 | 343 Million CNY | -16.17% |
| 2023 Q3 | 409.18 Million CNY | -8.77% |
| 2022 FY | 2.3 Billion CNY | 22.86% |
| 2022 Q3 | 511.94 Million CNY | -12.44% |
| 2022 Q2 | 584.66 Million CNY | 5.88% |
| 2022 Q1 | 552.22 Million CNY | 9.01% |
| 2022 Q4 | 654.71 Million CNY | 27.89% |
| 2021 Q4 | 506.56 Million CNY | 2.26% |
| 2021 Q1 | 391.2 Million CNY | -22.47% |
| 2021 Q3 | 495.36 Million CNY | 2.82% |
| 2021 FY | 1.87 Billion CNY | 12.43% |
| 2021 Q2 | 481.8 Million CNY | 23.16% |
| 2020 Q4 | 504.56 Million CNY | -0.74% |
| 2020 Q3 | 508.35 Million CNY | -0.1% |
| 2020 Q2 | 508.83 Million CNY | 248.88% |
| 2020 FY | 1.66 Billion CNY | -0.45% |
| 2020 Q1 | 145.85 Million CNY | -72.53% |
| 2019 Q1 | 366.67 Million CNY | 15.47% |
| 2019 FY | 1.67 Billion CNY | 26.74% |
| 2019 Q4 | 531.01 Million CNY | 76.23% |
| 2019 Q3 | 301.32 Million CNY | -36.72% |
| 2019 Q2 | 476.13 Million CNY | 29.85% |
| 2018 Q1 | 338.08 Million CNY | 9.66% |
| 2018 FY | 1.32 Billion CNY | 24.05% |
| 2018 Q4 | 317.54 Million CNY | -3.61% |
| 2018 Q3 | 329.44 Million CNY | -2.12% |
| 2018 Q2 | 336.59 Million CNY | -0.44% |
| 2017 Q3 | 240.18 Million CNY | -12.1% |
| 2017 Q1 | 243.7 Million CNY | 2.56% |
| 2017 FY | 1.06 Billion CNY | 37.23% |
| 2017 Q2 | 273.25 Million CNY | 12.13% |
| 2017 Q4 | 308.31 Million CNY | 28.36% |
| 2016 FY | 776.38 Million CNY | 2.55% |
| 2016 Q1 | 156.7 Million CNY | -33.22% |
| 2016 Q3 | 176.43 Million CNY | -14.2% |
| 2016 Q2 | 205.63 Million CNY | 31.23% |
| 2016 Q4 | 237.61 Million CNY | 34.68% |
| 2015 Q2 | 167.06 Million CNY | 1.97% |
| 2015 FY | 757.05 Million CNY | -7.07% |
| 2015 Q4 | 234.65 Million CNY | 22.54% |
| 2015 Q3 | 191.49 Million CNY | 14.62% |
| 2015 Q1 | 163.84 Million CNY | -20.96% |
| 2014 Q2 | 194.43 Million CNY | -6.06% |
| 2014 Q4 | 207.28 Million CNY | 0.67% |
| 2014 FY | 814.6 Million CNY | -5.36% |
| 2014 Q1 | 206.98 Million CNY | 3.91% |
| 2014 Q3 | 205.9 Million CNY | 5.9% |
| 2013 Q2 | 235.37 Million CNY | -0.1% |
| 2013 Q3 | 190.6 Million CNY | -19.02% |
| 2013 Q4 | 199.18 Million CNY | 4.5% |
| 2013 FY | 860.78 Million CNY | 18.14% |
| 2013 Q1 | 235.61 Million CNY | -4.05% |
| 2012 Q2 | 184.48 Million CNY | 9.8% |
| 2012 Q3 | 130.52 Million CNY | -29.25% |
| 2012 Q1 | 168.01 Million CNY | 8.34% |
| 2012 FY | 728.59 Million CNY | -1.23% |
| 2012 Q4 | 245.57 Million CNY | 88.14% |
| 2011 FY | 737.65 Million CNY | -35.56% |
| 2011 Q2 | 195.8 Million CNY | -14.75% |
| 2011 Q1 | 229.67 Million CNY | -7.83% |
| 2011 Q3 | 157.08 Million CNY | -19.77% |
| 2011 Q4 | 155.07 Million CNY | -1.28% |
| 2010 Q3 | 231.41 Million CNY | -27.19% |
| 2010 Q1 | 346.33 Million CNY | 47.22% |
| 2010 FY | 1.14 Billion CNY | 53.91% |
| 2010 Q4 | 249.18 Million CNY | 7.68% |
| 2010 Q2 | 317.83 Million CNY | -8.23% |
| 2009 Q4 | 235.24 Million CNY | 39.62% |
| 2009 Q3 | 168.48 Million CNY | 0.0% |
| 2009 FY | 743.79 Million CNY | 57.7% |
| 2008 FY | 471.64 Million CNY | 65.14% |
| 2007 FY | 285.59 Million CNY | 0.0% |